Table 4.
Log-lank Test and Univariate and Multivariate Analysis for Progression Free Survival.
| Factor | Category | Median PFS, m (95% CI) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| p value | HR (95% CI) | p value | ||||
| Histology | Adeno | 27.9 (15.2-NA) | 1 | |||
| Squamous | 9.63 (5.88-13.9) | <0.01 | 2.11 (1.18-3.78) | <0.05 | ||
| Age (years) | <63 | 27.9 (9.63-NA) | ||||
| ≥63 | 13.9 (7.95-25.1) | 0.21 | ||||
| Gender | Female | 14.1 (7.20-27.9) | ||||
| Male | 19.1 (9.53-28.0) | 0.58 | ||||
| ECOG-PS | 0, 1 | 16.6 (10.2-27.9) | ||||
| 2, 3 | 4.57 (1.23-NA) | 0.28 | ||||
| Alb (mg/dL) | ≥3.8 | 19.1 (9.53-28.0) | ||||
| <3.8 | 13.0 (7.20-27.9) | 0.68 | ||||
| CRP (mg/dL) | ≤0.05 | NA (20.4-NA) | ||||
| >0.05 | 13.9 (9.03-25.1) | 0.06 | ||||
| GPS | 0 | 23.5 (11.1-NA) | ||||
| 1, 2 | 10.2 (5.82-25.1) | 0.09 | ||||
| Hb (mg/dL) | ≥12.9 | 28.0 (10.2-NA) | 1 | |||
| <12.9 | 11.9 (7.20-23.5) | <0.05 | 1.10 (0.95-1.28) | 0.27 | ||
| PD-L1 (%) | >1 | 15.6 (9.03-NA) | ||||
| ≤1 | 6.97 (4.40-13.9) | 0.11 | ||||
| T factor | T1-T3 | 20.4 (10.1-NA) | ||||
| T4 | 13.0 (6.21-27.9) | 0.21 | ||||
| N factor | N3 | NA (4.67-NA) | ||||
| N0-2 | 13.6 (8.84-20.4) | 0.06 | ||||
Age, ECOG-PS, Alb, CRP, Hb, PD-L1, T factor and N factor were divided into two groups where the most difference occurred with reference to ROC curve. m: months, HR: hazard ratio, CI: confidence interval, ECOG: Eastern Cooperative Oncology Group, PS: performance status, Alb: albumin, CRP: C-reactive protein, GPS: Glasgow Prognostic Score, Hb: hemoglobin, PD-L1: programmed cell death ligand 1